Altimmune, Inc. (NASDAQ:ALT - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2025 EPS estimates for Altimmune in a note issued to investors on Thursday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.33) for the quarter, up from their previous forecast of ($0.34). HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Altimmune's Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.24) EPS, Q1 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.37) EPS.
Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.09. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period last year, the firm posted ($0.34) earnings per share.
ALT has been the topic of several other reports. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Wall Street Zen upgraded shares of Altimmune from a "sell" rating to a "hold" rating in a research report on Thursday. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $20.20.
View Our Latest Stock Analysis on ALT
Altimmune Trading Down 1.0%
ALT traded down $0.06 during midday trading on Monday, hitting $5.71. 1,651,677 shares of the company traded hands, compared to its average volume of 2,818,663. The company has a market capitalization of $463.12 million, a price-to-earnings ratio of -3.68 and a beta of 1.13. Altimmune has a 52-week low of $3.55 and a 52-week high of $11.16. The business has a 50 day simple moving average of $5.11 and a two-hundred day simple moving average of $6.52.
Institutional Investors Weigh In On Altimmune
Several hedge funds and other institutional investors have recently bought and sold shares of ALT. Ameriprise Financial Inc. increased its position in Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after purchasing an additional 1,378,854 shares during the last quarter. RFG Advisory LLC acquired a new stake in shares of Altimmune during the first quarter valued at about $1,622,000. Nuveen LLC acquired a new stake in shares of Altimmune during the first quarter valued at about $1,304,000. Invesco Ltd. increased its position in shares of Altimmune by 679.2% during the fourth quarter. Invesco Ltd. now owns 247,086 shares of the company's stock valued at $1,781,000 after acquiring an additional 215,375 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Altimmune by 139.8% during the fourth quarter. Millennium Management LLC now owns 345,637 shares of the company's stock valued at $2,492,000 after acquiring an additional 201,484 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, CFO Gregory L. Weaver acquired 10,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.10% of the stock is owned by company insiders.
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
See Also
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
